Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as penicillin G, benzathine benzylpenicillin
penicillin G benzathine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| active treatment arm | EXPERIMENTAL | penicillin G benzathine treatment |
| Name | Type | Description |
|---|---|---|
| penicillin G benzathine | DRUG | 2.4 million units (IM) of benzathine benzylpenicillin |
Inclusion Criteria: * Healthy female subjects (of childbearing or nonchildbearing potential) and/or male subjects * Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg and \<100 kg. Exclusion Criteria: • Evidence or history of clinically significant hematological, renal, ...
Penicillin G benzathine is a small molecule antibiotic developed by Pfizer, Inc. (ticker PFE). It is an intramuscular injectable form of penicillin. The program is in Phase 1 clinical development, and the specific indications being studied are undisclosed. It is investigational and has not been approved for the indications under study.
Penicillin G benzathine is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the sponsor of the clinical program for this injectable antibiotic.
Penicillin G benzathine is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The program remains investigational and has not been approved for the undisclosed indications being studied.
Penicillin G benzathine has been studied in one completed Phase 1 trial, NCT03612557, titled A Study of Benzathine Benzylpenicillin Intramuscular Injection in Japanese Healthy Subjects. The trial enrolled 8 healthy volunteers in Japan, was uncontrolled, and was not randomized or double blinded.
Penicillin G benzathine is an investigational product in Phase 1 clinical development and has not been approved for the undisclosed indications under study. The only listed trial, NCT03612557, was a completed Phase 1 study in healthy Japanese subjects.